Therefore, we investigated whether the levels of GPX1 were associated with prostate cancer recurrence in a TMA that was specifically designed to assess this endpoint, with the results indicating no difference in GPX1 levels between recurrent and non-recurrent cases. Here, GPX1 is linked to prostate carcinoma.